SELLAS Life Sciences Group, Inc (SLS) Financials
SLS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 8.1 million | 11.9 million |
2023-06-30 | 18.6 million | 13.7 million |
2023-03-31 | 29.1 million | 15.9 million |
2022-12-31 | 20.9 million | 16.1 million |
SLS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -9.9 million | 543000 |
2023-06-30 | -7.6 million | 514000 |
2023-03-31 | -12.1 million | 540000 |
2022-12-31 | -9.7 million | 446000 |
SLS Net Income
No data available :(
SLS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 4.0 million | - | 644000 |
2023-06-30 | 13.8 million | - | 749000 |
2023-03-31 | 23.9 million | - | 849000 |
2022-12-31 | 17.1 million | - | 945000 |
SLS Shares Outstanding
SLS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 3.0 million | 5.8 million | 3.5 million | - |
2023-06-30 | - | 5.9 million | 3.1 million | - |
2023-03-31 | - | 7.2 million | 4.1 million | - |
2022-12-31 | 4.5 million | 5.8 million | 3.6 million | - |
SLS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | - |
2023-06-30 | - | 158000 |
2023-03-31 | - | 87000 |
2022-12-31 | -1.0 million | 100000 |
SLS
Price: $1.35
52 week price:
Earnings Per Share: -1.34 USD
P/E Ratio: -0.50
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 183300
Ebitda: -4.4 millionMarket Capitalization: 76.5 million